International Pharma Associations Lay Principles For Publishing Trial Data, Regardless Of Outcome
This article was originally published in PharmAsia News
HONG KONG - Multinational pharmaceutical companies may start submitting for publication the results of more clinical trials, whether they are successful or not, as part of a new set of principles endorsed by industry associations around the world
You may also be interested in...
FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?
FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters
The International Federation of Pharmaceutical Manufacturers & Associations' Council on Nov. 10 expanded the group's clinical trials disclosure policy to cover all clinical trials, other than exploratory trials
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).